About Allurion
Allurion is a publicly listed company based in Wellesley (United States) founded in 2009. Satiety induction through digestable gastric balloon introduced via a swallowed capsule. Allurion has raised $174.04 million across 19 funding rounds from investors including SVB, RTW Investments and Bridge Bank. The company has 137 employees. Its website allurion.com draws about 13 thousand monthly visits. Its focus areas include Life Sciences, Obesity, Medical Devices and Therapeutic Devices. Its legal entity is ALLURION TECHNOLOGIES, INC. Its competitors include Apollo Endo, GT Metabolic Solutions and Spatz FGIA; 2 of its 3 listed competitors have raised funding.
Company details
Allurion Technologies was founded in 2009 in Wellesley, United States, focusing on medical devices in the weight management sector. The Elipse intragastric balloon is developed as a non-surgical option, swallowed via capsule and filled with liquid through a catheter. It remains in the stomach for around four months before emptying and passing naturally. The device is integrated with physician-supervised weight loss programs, avoiding endoscopy or anesthesia.
- Annual Revenue$32.11 M (USD)-39.94as on Dec 31, 2024
- Net Profit-$7.2 M (USD)91.48as on Dec 31, 2024
- EBITDA-$45.25 M (USD)42.22as on Dec 31, 2024
- Total Equity Funding$174.04M (USD)
in 19 rounds
- Latest Funding Round$5M (USD), Post-IPO
Nov 2025
- InvestorsSVB
& 9 more
- Employee Count137
Apps and channels of Allurion
its YouTube channel Allurion Program has 7.36K subscribers and 30 videos.
Videos from Allurion
The most watched videos on Allurion's YouTube channel, Allurion Program (7.36K subscribers). Click a video to play it here.
More on Allurion Program.
Funding Insights of Allurion
Allurion has successfully raised a total of $174.04M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $174.04M
- Total Rounds 19
- Last Round Post-IPO — $5M
- First Round $1.66M
(Jul 2012)
- Investors Count 10
Latest 10 of 19 funding rounds of Allurion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | $5M | Post-IPO | – | – | – |
| Jan 2025 | $2.5M | Post-IPO | – | – | |
| Apr 2024 | $48M | Post-IPO | – | – | |
| Dec 2023 | $122,513 | Post-IPO | – | – | – |
| Apr 2021 | $25M | Debt – Conventional | – | – | |
| Jan 2020 | $34M | Series D | – | Novalis LifeSciences, Romulus Capital | |
| Jan 2020 | Debt – Conventional | – | – | ||
| Sep 2019 | $60M | Series D | – | REMUS | – |
| Oct 2017 | $6M | Debt – Conventional | – | – | |
| Jul 2017 | $27M | Series C | – | REMUS |
10 investors in total: 9 institutional and 1 angel.
Investors in Allurion
Allurion has secured backing from 10 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include SVB, RTW Investments and Bridge Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Investment and advisory services are provided for life sciences. | 2017 | novalislifesciences.com | Portsmouth, USA | |
Early-stage VC firm investing in the US | romuluscap.com | Boston, United States | ||
Startups are targeted for investments by this venture capital firm. | ido.om | Muscat, Oman | ||
Multiple sectors are invested in by REMUS venture capital fund. | remuscap.com | Boston, United States | ||
| cogepa.com | ||||
Venture debt financing is provided to companies across multiple sectors. | 2015 | runwaygrowth.com | Woodside, United States | |
Commercial bank | 2001 | bridgebank.com | San Jose, United States | |
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
JA Jose Almeida | Angel investor in Indian startups, focused on tech and innovation. | unknown_28b875b7282048f3b |
Investor details for Allurion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Allurion
50 people are tracked at Allurion (10 in leadership, 15 in board & advisors, 25 in team); the tracked headcount is 137.
| Name | Role | Group |
|---|---|---|
Shantanu Gaur | CEO | Leadership |
Ram Chuttani | Chief Medical Officer & Founding Partner | Leadership |
Javier Ibañez | Vice President Of International Sales | Leadership |
Nidal Naji | Regional Executive Director | Leadership |
Pearlrie T. | APAC Sales Director | Leadership |
Camillo Docimo | Vice President Global Program Excellence And Business Development | Leadership |
Bill Nadeau | Vice President, Medical Affairs | Leadership |
Matthew Wright Bsc. Cipd Qualified | Global Vice President - People, Talent, Learning & Culture (global Head Of Hr) | Leadership |
Stephanie Rockwern Amlung | Senior Director, Clinical Affairs | Leadership |
Saleem Mustafa | Regional Sales Director Mea, Turkey & APAC | Leadership |
Michael Davin | Director | Board & advisors |
Richard Rothstein | Medical Advisor | Board & advisors |
Jordan Busch | Medical Advisor | Board & advisors |
Jaime Ponce | Medical Advisor | Board & advisors |
Harold Solomon | Medical Advisor | Board & advisors |
Bruce Schirmer | Medical Advisor | Board & advisors |
Peter D. Siersma | Medical Advisor | Board & advisors |
Nezam Afdhal | Medical Advisor | Board & advisors |
Daniel Jones | Medical Advisor | Board & advisors |
John Morton | Medical Advisor | Board & advisors |
30 more people are available in the full profile.
Complete people profiles for Allurion
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Allurion
Allurion is a publicly listed company on the NYSE with ticker symbol ALUR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Aug 2023
- Listed onNASDAQ: ALUR
- Listed entityAllurion Technologies, Inc.
- Exchange sectorHealth technology
- ISINUS02008G2012
- Share price$0.67 (-5.63% on the day) · 2026-03-09
- Market capitalisation$8.2M
- EPS (diluted, trailing year)$-7.33
- Volume (last session)236,456
- Analyst consensusStrong buy
Financials of Allurion
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $32.1M | -$7.2M | -$45.2M |
| 2023 | $53.5M | -$84.5M | -$78.3M |
| 2022 | $64.2M | -$40.6M | -$31.1M |
Detailed financial statements for Allurion
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Allurion
4 dated milestones of Allurion across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Allurion is founded.
- Funding First funding round of $1.7M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $5.0M.
Competitors of Allurion
Allurion has 3 listed competitors in our database, 2 of them funded. They include Apollo Endo, GT Metabolic Solutions and Spatz FGIA.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| apolloendo.com | 2005 | Austin, United States | $80.36M | 132 | Therapeutic devices for obesity and GI disorders are developed. | |
| gtmetabolic.com | 2020 | Saint Michael, United States | $17.08M | Incision-less bariatric surgery technology is developed for gastric bypass. | ||
| spatzmedical.com | 2005 | Great Neck, United States | Minimally invasive gastric balloon is developed for obesity satiety induction. |
Detailed competitors of Allurion
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Allurion
The website of Allurion (allurion.com) receives about 12.9K visits a month.
- Monthly visits12.9K
▼ 3.4% vs previous month
Websites whose visitors overlap most with Allurion. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mexicobariatriccenter.com | 100% | #664,117 | View details | ||
lightclinic.net | lightclinic.net | 100% | – | ||
clinicafornaca.it | clinicafornaca.it | 70% | #674,318 | – | |
aslbi.piemonte.it | aslbi.piemonte.it | 66% | #756,005 | – | |
| clinicaltrialsarena.com | 60% | #257,942 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Allurion
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Allurion (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | USD 761.41 M | 500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Allurion
Complete news archive for Allurion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allurion
Allurion was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Allurion is headquartered in Wellesley, United States. It is registered at Wellesley, Massachusetts, United States.
Allurion is a funded company, having raised a total of $174.04M across 19 funding rounds to date. The company's 1st funding round was a Series C of $27M, raised on Jul 2012.
Allurion has 137 employees.
Annual revenue of Allurion is $32.11M as on Dec 31, 2024.
Allurion Technologies was founded in 2009 in Wellesley, United States, focusing on medical devices in the weight management sector. The Elipse intragastric balloon is developed as a non-surgical option, swallowed via capsule and filled with liquid through a catheter. It remains in the stomach for around four months before emptying and passing naturally. The device is integrated with physician-supervised weight loss programs, avoiding endoscopy or anesthesia.
Allurion's top competitors include Apollo Endo, GT Metabolic Solutions and Spatz FGIA.
Yes, Allurion is publicly traded on NYSE under the ticker symbol ALUR.
Allurion has 10 investors. Key investors include SVB, RTW Investments, Bridge Bank, Runway Growth Capital, and Novalis LifeSciences.
Allurion operates through Allurion Technologies, Inc.